Biological AbnormalityORANCT07405996
Referral of Patients With Biological Abnormalities to an Emergency Department
An observational study of Biological Abnormality and Emergency Department Visit, run by Centre Hospitalier Régional Metz-Thionville at 1 site in France.
Trial summary
Biological testing is an essential part of general medical practice and plays a role in 60% to 70% of diagnoses. 68.5% of prescriptions are written by general practitioners, and one in seven general medical consultations ends with a prescription for biological testing. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Biological Abnormality, Emergency Department Visit, General Practitioner
- How many people
- 5,000 participants
- Where
- 1 siteFrance
- Study dates
- 1 Feb 2026to 1 Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Any patient presenting at an emergency department participating in the IOA (nurse coordinating reception) system with the reason for referral "Abnormal laboratory results.
Who may be able to join
- Any patient presenting at an emergency department participating in the IOA (nurse coordinating reception) system with the reason for referral "Abnormal laboratory results.
Who cannot join
- minor patients (<18 years old)
- expression of the patient's opposition to the collection of data relating to their hospital stay.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Laure ABENSUR VUILLAUME contact
About this study
Official title: Referral of Patients With Biological Abnormalities to an Emergency Department : ORA
Biological testing is an essential part of general medical practice and plays a role in 60% to 70% of diagnoses. 68.5% of prescriptions are written by general practitioners, and one in seven general medical consultations ends with a prescription for biological testing. The study of patient trajectories is a recent emerging topic in the literature, encompassing general concepts. The angle most often taken is medico-economic and focused on specific chronic conditions such as diabetes, cancer, or cardiovascular disease. To our knowledge, there are a number of referrals to emergency departments by general practitioners for patients with biological abnormalities. However, to our knowledge, no study to date has attempted to quantify these specific referrals.
Read the detailed description
want to establish a register of biological anomaly referrals by general practitioners to emergency departments. This study will enable us to estimate the number of patients whose referral could have been handled differently, allowing us to develop dedicated care pathways, specialized training in outpatient settings, or targeted communications, ultimately leading to better patient referral and reducing inappropriate use of emergency services.
What is being measured
The primary outcome is the main question the study is designed to answer.
Type of biological abnormality and severity level
The primary evaluation criterion is the type of biological abnormality sent to the emergency department and its severity (depth or elevation).
Measured: Immediately upon admission to the emergency room
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2026
- Study start1 Feb 2026 (estimated)
- Primary completion1 Feb 2027 (estimated)
- Study completion1 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Biological AbnormalityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Régional Metz-Thionville
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07405996
- Sponsor's protocol ID
- 2025-06-Obs-CHRMT
- Acronym
- ORA
- Status last verified
- Jan 2026
- First submitted
- 27 Jan 2026
- Last updated
- 12 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Referral of Patients With Biological Abnormalities to an Emergency Department : ORA
- ClinicalTrials.gov ID
- NCT07405996
- Acronym / sponsor ID
- ORA / 2025-06-Obs-CHRMT
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- Centre Hospitalier Régional Metz-ThionvilleUniversity, hospital or other
- Study start
- 1 Feb 2026 (estimated)
- Primary completion
- 1 Feb 2027 (estimated)
- Study completion
- 1 Feb 2027 (estimated)
- First posted
- 12 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Biological testing is an essential part of general medical practice and plays a role in 60% to 70% of diagnoses. 68.5% of prescriptions are written by general practitioners, and one in seven general medical consultations ends with a prescription for biological testing. The study of patient trajectories is a recent emerging topic in the literature, encompassing general concepts. The angle most often taken is medico-economic and focused on specific chronic conditions such as diabetes, cancer, or cardiovascular disease. To our knowledge, there are a number of referrals to emergency departments by general practitioners for patients with biological abnormalities. However, to our knowledge, no study to date has attempted to quantify these specific referrals.
Detailed description
want to establish a register of biological anomaly referrals by general practitioners to emergency departments. This study will enable us to estimate the number of patients whose referral could have been handled differently, allowing us to develop dedicated care pathways, specialized training in outpatient settings, or targeted communications, ultimately leading to better patient referral and reducing inappropriate use of emergency services.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Any patient presenting at an emergency department participating in the IOA (nurse coordinating reception) system with the reason for referral "Abnormal laboratory results.
Key inclusion criteria (1 listed)
- Any patient presenting at an emergency department participating in the IOA (nurse coordinating reception) system with the reason for referral "Abnormal laboratory results.
Key exclusion criteria (2 listed)
- minor patients (<18 years old)
- expression of the patient's opposition to the collection of data relating to their hospital stay.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Type of biological abnormality and severity level
Time frame: Immediately upon admission to the emergency room
The primary evaluation criterion is the type of biological abnormality sent to the emergency department and its severity (depth or elevation).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Biological Abnormality
Recruiting
Institution of an Italian Registry and Biobank for Biological Sample Collection
Lymphatic Malformation, Lymphatic Abnormality
Active, not recruitingObservational study
Network Of Clinical Research Studies On Craniosynostosis, Skull Malformations With Premature Fusion Of Skull Bones
Craniosynostosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Laure ABENSUR VUILLAUME contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Biological Abnormality and Emergency Department Visit, run by Centre Hospitalier Régional Metz-Thionville at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andreia CARVALHO DE FREITAS (0033387553323, projet-recherche-clinique@chr-metz-thionville.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Type of biological abnormality and severity level (time frame: Immediately upon admission to the emergency room). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2026.